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The increased prevalence of obesity and its cardiometabolic implications demonstrates the im-
perative to identify novel therapeutic targets able to effect meaningful metabolic changes in this
population. Antibody-mediated targeting of fibroblast growth factor receptor 1c isoform (FGFR1c)
has been shown to ameliorate hyperglycemia and protect from diet- and genetically-induced
obesity in rodents and nonhuman primates. However, it is currently unknown which tissue(s)
contribute to this glucose-lowering effect. Thus, to elucidate this effect, we treated euglycemicmice
with H7, a monoclonal antibody that selectively targets FGFR1c, and used whole-body positron
emission computed tomographywith a glucose tracer (18F-fluorodeoxyglucose). Treatment with H7
increased basal glucose uptake inwhite adipose tissue (WAT), brown adipose tissue (BAT), the brain,
and liver but reduced it in the quadriceps muscles. Consequentially, blood glucose was significantly
reduced in response to treatment. Under insulin-stimulated conditions, the effects of H7 were
maintained in WAT, BAT, liver, and muscle. Treatment with H7 decreased triglyceride (TG) content
and increased adipose TG lipase content inwhite adipose tissue,while increasing activation of acetyl
coenzyme A carboxylase, suggesting futile cycling of TGs, albeit favoring net hydrolysis. We
demonstrated, in vitro, this is a direct effect of treatment in adipose tissue, as basal cellular res-
piration and glucose uptake were increased in response to treatment. Taken together, these data
suggest that antibody-mediated targeting of FGFR1c exerts its powerful glucose-lowering efficacy
primarily due to increased glucose uptake in adipose tissue. (Endocrinology 158: 3090–3096, 2017)
The fibroblast growth factor (FGF) family is a diversearray of autocrine, paracrine, and endocrine factors
reported to play key roles in the development, growth,
and metabolic homeostasis (1). The activity of FGFs is
dependent upon engagement of tyrosine kinase FGF re-
ceptors (FGFRs), with the FGFR1c isoform being pro-
posed to be the primary FGFR accounting for the
metabolic actions of the so-called endocrine family of
FGFs (2, 3). In accordance with its metabolic mode of
action, the FGFR1c is expressed by several metabolically
active organs, including white adipose tissue (WAT) and
brown adipose tissue (BAT), as well as the hypothalamus
(4), an area of the central nervous system associated with
regulation of appetite. Recently, with the aim of un-
derstanding the role of the FGFR1c in the regulation of
energy homeostasis, we used peripheral and central ad-
ministration of a monoclonal antibody (H7) that selectively
targets this isoform. We found that targeting of FGFR1c in
the Siberian hamster, a natural model of adiposity, results
in a profound antiobesogenic phenotype, accompanied by a
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substantial reduction in fed blood glucose levels and a clear
suppression of daily food intake (5). In support of these
data, administration ofH7 tomousemodels of obesity and
diabetes reduces body weight, fat mass, blood glucose
levels, and insulin resistance (6–8). However, it is un-
known which tissue(s) are responsible for this antidiabetic
activity. Mice with adipose-selective FGFR1 knockout are
refractory to the antidiabetic activity of FGF21, a natural
ligand for FGFR1c (8). Therefore, it appears that adipose
tissue might be an important target for H7. Thus, the aim
of this study was to ascertain the tissue-specific glucose
uptake effects in response to peripherally targeting
FGFR1c under basal and insulin-stimulated conditions,
with particular emphasis on WAT and BAT utilizing in
vivo and in vitro approaches. To account for any adverse
effects of obesity-induced insulin resistance on tissue
glucose uptake, a lean euglycemic animal model was
selected to fulfill the objective of this study.
Research Design and Methods
Animals and experimental protocol
All studies were approved by the University of Nottingham
AnimalWelfare and Ethical Review Board and were carried out
in accordance with the UK Animals (Scientific Procedures) Act
of 1986 (project license PPL 40/3604). Age-matched adult male
C57BL/6 euglycemic mice were randomly divided into one of
two treatment groups in which they received a single sub-
cutaneous injection of either vehicle (n = 8) or H7 (n = 8; 3 mg/kg),
as previously described (6). After 24 hours, a subset of animals
from each treatment group (n = 4 per group) were transferred to
metabolic cages (Comprehensive LaboratoryAnimalMonitoring
System; Linton Instrumentation, Linton, United Kingdom; Co-
lumbus Instruments, Columbus, OH) to measure daily energy
expenditure. Seventy-two hours post injection, following a
4-hour fast, all animals were transferred to the nano–positron
emission tomography/computed tomography (PET/CT) imaging
unit (Mediso Medical Imaging Systems, Budapest, Hungary) to
quantify glucose uptake in response to intraperitoneal infusion of
18F-fluorodeoxyglucose (18F-FDG) (10 MBq per animal) under
basal (n = 4 per treatment) and insulin-stimulated conditions
(subcutaneous injection, 0.75 U/kg, 10 minutes post 18F-FDG
infusion, n = 4 per treatment). All scans lasted 60 minutes and
were initiated 10 minutes post infusion of 18F-FDG. The mag-
nitude of tissue-specific 18F-FDG uptake was expressed as the
standard uptake value defined as the average 18F-FDG activity in
each region of interest (in kBq/cm3) divided by the injected dose
(kBq) and multiplied by the body weight of each animal (kg).
Animals were subsequently euthanized, and blood was obtained,
via cardiac puncture, tomeasure glucose (HemoCUE201System;
HemoCUE, Angelholm, Sweden), plasma insulin, and tumor
necrosis factor a (TNF-a) (Millipore, Billerica,MA). Triglyceride
(TG) content of excised liver, adipose tissue, and muscle tissue
was performed as previously described (9).
Mitochondrial function assay
Mouse 3T3-L1 fibroblasts (ATCC, Manassas, VA) were
differentiated for 10 days and treated with vehicle, 10 nM
immunoglobulin G1 (IgG1), or 10 nM H7 for 24 hours,
followed by assessment of glucose uptake as previously de-
scribed (10) and mitochondrial function via the mitochon-
drial stress test (Seahorse XF Cell Mito Stress Test Kit; part
no. 103015-100; Agilent Technologies, Inc., Wilmington,
DE) (n = 14 per treatment).
Western blotting
Proteins were extracted from WAT using a HEPES lysis
buffer and quantified using the bicinchoninic acid protein assay
(catalog no. 23227; Pierce, Thermo Fisher Scientific Inc.,
Waltham, MA). Western blotting was performed and resulting
membranes were probed overnight at 4°C with primary anti-
bodies (1:1000 dilution) to adipose TG lipase (ATGL; catalog
no. ab109251; Abcam, Cambridge, UK), phospho-acetyl co-
enzyme A carboxylase (pACC; catalog no. 3661; New England
Biolabs, Ipswich,MA), and cyclophilin B (CYC; 1:4000; catalog
no. ab74173; Abcam). Blots were then washed and incubated
for 1 hour with anti-rabbit (ATGL and pACC) and anti-mouse
(CYC) horseradish peroxidase secondary antibody (Dako Den-
mark A/S, Glostrup, Denmark) at 1:2000 dilution. All immu-
noreactive proteins were detected using ECL Prime Western
Blotting Detection Reagent (catalog no. RPN2232; GE Health-
care,Chicago, IL), quantified bydensitometry using anAida Image
Analyzer (version 4.27), and normalized to CYC.
Statistical analysis
Descriptive statistics (mean 6 standard error of the mean)
were generated using GraphPad Prism (Prism 6.0; GraphPad,
San Diego, CA). Body weight, food intake, and metabolic cage
data were analyzed using two-way (treatment 3 time) repeated
measures analysis of variance (ANOVA). Tissue weights and
protein content, blood glucose, plasma insulin and TNF-a,
tissue TG content, and 18F-FDG uptake were analyzed using a
Student t test. All image analysis was performed blinded to
treatment using VivoQUANT software (inviCRO, Boston,
MA). Glucose uptake in adipocytes was analyzed using one-way
ANOVA. Maximal cell oxygen consumption rate (OCR), an-
alyzed using both the area under the curve and the peak values
(oxidative capacity), basal cellular respiration, adenosine tri-
phosphate (ATP) generation, and nonmitochondrial respiration
were analyzed using a one-way ANOVA. Statistical significance
was declared at P , 0.05.
Results
Body weight was decreased by approximately 14% com-
pared with vehicle-treated controls (P, 0.0001). Similarly,
food intake was reduced by 34% during the 72-hour ex-
perimental period (P , 0.0001), resulting in reduced vis-
ceral WAT weight (43%, P , 0.0001). Although there
was a clear diurnal variation in whole-body energy ex-
penditure in both vehicle- and H7-treated mice, there was
no effect of acute treatment with H7 on energy expenditure
during the final 24 hours of the experimental period.
Treatment with H7 resulted in a 70% decrease in plasma
insulin anda50%decrease inTNF-a (P,0.05, respectively).
Similarly, basal blood glucose concentrations were also
reduced by 53% in animals treated with H7 (Fig. 1A;
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P , 0.01), and they were further reduced (by 63%) in
the insulin-stimulated group (Fig. 1A; P , 0.05).
In WAT and interscapular BAT, treatment increased
18F-FDG uptake compared with vehicle-treated controls
(Fig. 1B and 1C; P , 0.01). This effect was maintained
under insulin-stimulated conditions (Fig. 1B and 1C, P,
0.05). In the brain, under basal conditions, treatment
with H7 significantly increased 18F-FDG uptake com-
pared with vehicle-treated controls (Fig. 1D; P , 0.05).
However, there was no difference under insulin-
stimulated conditions (Fig. 1D). Similarly, treatment
with H7 increased hepatic 18F-FDG uptake compared
with vehicle-treated controls both under basal (Fig. 1E;
P, 0.01) and insulin-stimulated conditions (P, 0.05).
However, in the muscle, treatment with H7 reduced
18F-FDGuptake comparedwith vehicle-treated controls in
both basal (Fig. 1F; P , 0.05) and insulin-stimulated
conditions (Fig. 1F; P , 0.0001). Representative images
are shown in Fig. 2.
In line with in vivo data, treatment with H7 signifi-
cantly increased glucose uptake into 3T3-L1 adipocytes
when compared with vehicle and IgG1 (Fig. 3A; F =
16.33, P , 0.05), whereas there was no effect of treat-
ment on maximal adipocyte OCR (oxidative capacity)
(Fig. 3B and 3C). However, H7 increased (P , 0.05)
basal cellular respiration, ATP generation, and non-
mitochondrial respiration when compared with vehicle
and IgG1 (Fig. 3C).
Hepatic (saline, 44.8 6 1.7 mmol/g vs H7, 28.3 6
1.4mmol/g) andmuscle (saline, 34.56 1.1mmol/g vs H7,
23.7 6 1.8 mmol/g) TG content was also significantly
reduced by 37% and 31%, respectively, (P , 0.05) in
animals treated with H7. In WAT, TG content was
significantly reduced (Fig. 4A; P , 0.05), ATGL protein
content was significantly increased (Fig. 4B; P , 0.05),
and pACC was significantly reduced (Fig. 4C; P , 0.05)
in response to treatment with H7.
Discussion
This study demonstrates that antibody-mediated target-
ing of FGFR1c exerts a potent glucose-lowering effect as a
consequence of increased glucose uptake in white and
brown adipose tissue. This effect is associated with in-
creased basal cellular respiration, ATP generation, and
nonmitochondrial respiration but not maximal oxygen
consumption in adipocytes. However, there was no effect
of treatment on whole-body energy expenditure, a pos-
sible consequence of contrasting changes in substrate
utilization in other metabolically active tissues. Treat-
ment with H7 was associated with increased markers of
lipogenic (pACC) and lipolytic (ATGL) capacity inWAT,
suggesting a futile (re)cycling of its TG content. Taken
Figure 1. Effect of systemic treatment with a monoclonal antibody
that targets the FGFR1c (H7) on blood glucose and basal and insulin-
stimulated glucose uptake [expressed as standard uptake value (SUV)]
in WAT, interscapular BAT (iBAT), brain, liver, and skeletal muscle in
mice. (A) Blood glucose of adult male mice treated with vehicle or H7.
Values are group mean 6 standard error of the mean (SEM) (n = 4 per
treatment). *P , 0.05, **P , 0.01 vs vehicle. (B–F) 18F-FDG uptake in
(B) WAT, (C) iBAT, (D) brain, (E) liver, (F) and quadriceps muscles treated
with vehicle or H7. Values are group mean 6 SEM (n = 4 per
treatment). *P , 0.05, **P , 0.01, ****P , 0.0001 vs vehicle.
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together, these data provide support for the notion that
targeting this pathway in adipose tissue may have
therapeutic potential for the treatment of metabolic
syndrome (MetS).
It is now widely accepted that in addition to func-
tioning as a daily buffer for circulating lipids, adipose
tissue also plays a key role in the regulation of energy
balance and glucose homeostasis via release of circulating
metabolites and hormonal factors (11). Indeed, secreted
adipokines have been investigated intensively for their
roles in energy homeostasis (12) in an attempt to iden-
tify novel pathways for the treatment of obesity and
its associated comorbidities. The endocrine FGFs have
emerged as a novel family of hormonal factors that, when
administered to rodents, have substantial antidiabetic
activity (13). The downstream capabilities of FGF ligands
are highly dependent upon engagement of FGFR1c, the
predominant FGFR expressed in WAT and BAT (4).
Indeed, mice with adipose-selective FGFR1 knockout
were refractory to FGF21-induced improvements in
glucose metabolism and body weight (8).
We previously reported that targeting FGFR1c in the
Siberian hamster resulted in a profound antiobesogenic
phenotype, with reduced blood glucose levels (5). Al-
though this was supported by previous studies in mice
(6), it was unknown which tissue(s) were responsible
for this blood-glucose lowering effect and whether it
was secondary to reduced food intake and body weight.
The current study provides in vivo PET/CT data to
indicate that H7-mediated lowering
of blood glucose levels is predomi-
nantly associated with enhanced
basal and insulin-stimulated glucose
uptake in WAT and BAT. Although
previous studies have shown that
basal glucose uptake in WAT is low,
under certain conditions (e.g., stim-
ulation with insulin and compounds
such as b-agonists), this increases
(14). In WAT, the H7-mediated effect
observed in the current study is pre-
sumably a consequence of accelerated
rates of TG hydrolysis (as indicated by
the reduction in WAT weight and TG
content) coupled to resynthesis, requir-
ing large amounts of ATP (15). This
notion of futile (re)cycling is sup-
ported by the increase in the protein
content of ATGL (the rate-limiting
step in TG hydrolysis) and reduction
in pACC (indicating increased activity
of a key enzyme in de novo lipogenesis)
in WAT in response to treatment with
H7, albeit favoring net hydrolysis (as indicated by the
reduction in TG content). This futile cycling of TG
requires a significant amount of ATP, and the increase in
basal cellular respiration and ATP generation in 3T3-L1
adipocytes in response to H7 treatment supports this
mechanism. Furthermore, the increase in glucose uptake
in vitro demonstrates a direct effect of treatment rather
than a consequence of reduced food intake and body
weight in vivo.
Although the primary role of BAT is to maintain body
temperature during the adaptive response to cold expo-
sure, since its discovery in adult humans, it has emerged
as an attractive target organ for the treatment of MetS.
BAT displays a very high rate of glucose uptake, par-
ticularly under sympathetic activation (16). Furthermore,
it is known to exert anti–type 2 diabetes mellitus (T2D)
effects associatedwith improvements of dyslipidemia and
insulin secretion, as well as decreased insulin resistance in
T2D (17). In the current study, basal glucose uptake in
BAT was 20% higher than in WAT in response to
treatment. Furthermore, treatment was associated with
reduced plasma insulin and TNF-a. Increasing BAT ac-
tivity has advantageous effects on body composition and
insulin sensitivity in mice, which suggests that BAT is an
endocrine organ that can function to improve whole-
body and tissue glucose homeostasis, effects mediated
by TNF-a, interleukin-6, and the glucose transporter
GLUT1, which is known to regulate insulin-independent
glucose uptake (18, 19). It is likely that the redirection of
Figure 2. Representative whole-body PET/CT images of euglycemic mice receiving 18F-FDG
treated with (A) vehicle (saline), (B) H7 + vehicle (saline), (C) vehicle (saline) + insulin, and (D) H7 +
insulin. iBAT, interscapular BAT.
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glucose to energy combusting BAT without further
storage in skeletal muscle (which showed a reduction in
glucose uptake in response to treatment with H7) may
contribute to the weight loss and insulin-sensitizing effect
of H7. Overall, our data provides evidence that adipose
tissue plays a dominant role in mediating the effects of
targeting the FGFR1c, revealing the clinical potential of
this pathway for the treatment of T2D and other chronic
disorders linked to MetS and obesity.
Unlike adipose tissue, liver and skeletal muscle are
not likely to be direct targets tissues for the H7 actions.
Indeed, severe energy restriction (that is accompanied
by weight loss of similar magnitude to the one observed
in this study) leads to altered hepatic glucose uptake/
metabolism and a shift in substrate utilization in
skeletal muscle toward fat oxidation with a concomi-
tant reduction in the oxidation of glucose and the
development of insulin resistance in that tissue (20).
Future investigations are also required to determine the
precise role of FGFR1c-mediated glucose uptake in the
Figure 4. Effect of systemic treatment with a monoclonal antibody
that targets the FGFR1c (H7) on WAT TG and protein content. (A)
WAT TG content treated with vehicle or H7. (B) ATGL and (C) pACC
protein content of WAT treated with vehicle or H7. Representative
blots included. Values are group mean 6 SEM (n = 8 per treatment).
*P , 0.05 vs vehicle.
Figure 3. In vitro treatment of adipocytes with a monoclonal
antibody that targets the FGFR1c (H7) increases glucose uptake and
basal respiration but not maximal OCR. (A) Glucose uptake in
adipocytes treated with vehicle, IgG1, and H7. Values are group
mean 6 standard error of the mean (SEM) (n = 14 per treatment).
*P , 0.05 vs vehicle/IgG1. (B) OCR in adipocytes treated with
vehicle, IgG1, and H7. Values are group mean 6 SEM (n = 14 per
treatment). (C) Basal cellular respiration, ATP generation, maximal
oxidative capacity, and nonmitochondrial respiration in adipocytes
treated with vehicle, IgG1, and H7. Values are group mean 6 SEM
(n = 14 per treatment). *P , 0.05 vs vehicle and IgG1. FCCP,
carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone; Oligo,
oligomycin; Rot, rotenone plus antimycin; Veh, vehicle.
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brain and possible link to H7-mediated appetite
regulation.
Conclusion
The increasing prevalence of obesity and its comorbid-
ities, including, but not limited to, T2D, are predicted to
become two-thirds of the global burden of disease if
current dietary and lifestyle trends continue (21). Existing
therapies are unable to provide durable and robust
change in metabolic health, and therefore it remains
imperative to identify novel therapeutic agents able to
effect meaningful change. The current study highlights
the importance of adipose tissue FGFR1c as a target
for an effective treatment strategy for MetS by reducing
body weight, food intake, lipid accumulation, and thus
lipotoxicity in adipose and nonadipose tissues, while
lowering glycemia by enhancing glucose disposal pri-
marily in adipose tissue (22–24).
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